CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.
2 reports, 2 independent
Updated Sun 00:00
No new developments lately
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Market performance diverges based on outlooks, and an agreement was reached to provide Eliquis free to the program.1 source
- Major pharmaceutical companies are part of the ten largest global pharma giants as the industry seeks to weaken drug price negotiation.Sub-event
CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.1 source
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
-
Medicare
US federal health insurance
Related events
- AARP advocated for Medicare to negotiate drug prices in Washington, D.C.
- CMS proposes broadening criteria for price control, while CBO warns that such controls could discourage investment in the sector.
- Market competition observed in the large-cap healthcare sector involving Bristol-Myers Squibb and Orion OYJ.
- Tariffs are introducing uncertainty into the drug market structure.
- Negotiated prices are impacting market access and revenue for major pharmaceutical companies like Pfizer, UCB, Bristol-Myers Squibb, and Novartis.